

AP20 Res 17077382 27 APR 2006

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

3

Complete if Known

Application Number	NOT YET KNOWN
Filing Date	Herewith 10/15/2006
First Named Inventor	Shi Du Yan
Art Unit	
Examiner Name	
Attorney Docket Number	

Attorney Docket Number 68548-PCT-US/JPW/JW

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	International Search Report issued by the International Searching Authority (ISA/US) on April 7, 2005 in connection with International Application No. PCT/US2004/036173	
	2	Tsuji H, Ichara N, Masegi T, Imura M, Ohkawa J, Arai H, Ishii K, Kita T, and Doi T. (1998) Ribozyme Targeting of Receptor for Advanced Glycation End Products in Mouse Mesangial Cells. Biochem. Biophys. Res. Commun. 245: 583-588	
	3	Bierhaus A, Illmer T, Kasper M, Luther T, Quehenberger P, Tritschler H, Wahl P, Ziegler R, Müller M, and Nawroth PP. (1997) Advanced Glycation End Product (AGE)-Mediated Induction of Tissue Factor in Cultured Endothelial Cells Is Dependent on RAGE. Circulation 96: 2262-2271	
	4	Sajithlal G, Huttunen H, Rauvala H, and Münch G. (2002) Receptor for Advanced Glycation End Products Plays a More Important Role in Cellular Survival than in Neurite Outgrowth during Retinoic Acid-induced Differentiation of Neuroblastoma Cells. J. Biol. Chem. 277(9): 6888-6897	
	5	Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, and Schmidt AM. (1996) RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 382: 685-691	
	8	Jen K-Y and Gewirtz AM. (2000) Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Option and Current Strategies. Stem Cells 18: 307-319	
	9	Branch AD. (1998) A good antisense molecule is hard to find. TIBS 23: 45-50	
	10	Green DW, Roh H, Pippin J, and Drebin JA. (2000) Antisense Oligonucleotides: An Evolving Technology for the Modulation of Gene Expression in Human Disease. J. Am. Coll. Surg. 191(1): 93-105	
	11	Fire A. (1999) RNA-triggered gene silencing. TIG 15(9): 358-363	
	12	Caplen NJ, Fleenor J, Fire A, and Morgan RA. (2000) dsRNA-mediated gene silencing in cultured Drosophila cells: a tissue culture model for the analysis of RNA interference. Gene 252: 95-105	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Applicants: Shi Du Yan, et al.
U.S. Serial No. NOT YET KNOWN
Filed: Herewith (as §371 national stage of PCT/US2004/036173)
Exhibit A

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.E./

AP20 Rec'd PCT/PTO 27 APR 2006

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

3

Complete if Known

Application Number

NOT YET KNOWN 7382

Filing Date

Herewith

First Named Inventor

Shi Du Yan

Art Unit

Examiner Name

Attorney Docket Number 68548-PCT-US/JPW/JW

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	13	Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, and Mello CC. (1998) Potent and specific genetic interference by double-stranded RNA in <i>Caenorhabditis elegans</i> . <i>Nature</i> 391: 806-811	
	14	Lue L-F, Walker DG, and Rogers J. (2001) Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures. <i>Neurobiol. Aging</i> 22: 945-956	
	15	Carmeliet P, Moons L, and Collen D. (1998) Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostasis. <i>Cardiovasc. Res.</i> 39: 8-33	
	16	Written Opinion of the International Searching Authority issued by the International Searching Authority (ISA/US) on April 7, 2005 in connection with International Application No. PCT/US2004/036173	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.E./

